Myelodysplastic Syndrome Myelodysplastic Syndrome

Highlights in myelodysplastic syndrome from ASH 2020 include a survival benefit for reduced-intensity HSCT vs hypomethylating agents in older patients, and a promising combination for high-risk MDS.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news